CLL Management in Times of COVID-19: Frontline Acalabrutinib or Ven +/- Obi, Ibrutinib, How to Identify Barriers to Treatment Due to the Ongoing Pandemic?

101 views
March 18, 2021
0 Comments
Login to view comments. Click here to Login